A Double-Blind, Randomized, Placebo Controlled, 2-Period Crossover Study to Evaluate the Effect of a Single Dose of JNJ-28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Subjects.

Trial Profile

A Double-Blind, Randomized, Placebo Controlled, 2-Period Crossover Study to Evaluate the Effect of a Single Dose of JNJ-28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Sep 2012 Results will be presented at EASD-2012 according to a Janssen Research and Development media release.
    • 18 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Oct 2011 Actual patient number is 26 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top